Rifampicin as Potent Inhibitor of COVID - 19 Main Protease: In-Silico Docking Approach
Himesh Soni, Vikas Gautam, Sarvesh Sharma, Jitender K Malik
Abstract
) is an enveloped RNA virus that is diversely initiates in humans and wildlife. A total of 6 species have been identified to cause disease in humans. Viral infections play a critical role in human diseases, and recent outbreaks is the influx worldwide in form of novel corona .The SS-RNA virus from the enveloped corona virus family caused SARS (Severe acute respiratory syndrome) which is life threatening viral infection. The spreading of infection is quick in many countries of the world. The World Health Organization (WHO) called COVID-19 a pandemic on March 11, 2020. There are numerous drug trials going on with some positive results. Though, since no vaccine is available, the best way to fight the virus is by preventive measures. In the present research an attempt had been made to find new COVID-19 main protease inhibitor by molecular docking approach. The present study reveals that rifampicin has good binding affinity with COVID-19 protease and thus can be used as prophylaxis and therapeutic treatment for corona patient.